Fat Loss peptides

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

A fat-loss peptide. It's a modified fragment of HGH (residues 176-191) that targets fat metabolism without the full GH side effect profile.

An experimental fat-loss compound. An NNMT inhibitor that targets the enzyme driving metabolic stagnation in obesity, with animal and in-vitro data only and no published human results.

An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.

A weight-loss drug built for a stronger fat-burn signal than GLP-1-only options. A dual agonist (GLP-1 + glucagon) from Boehringer Ingelheim / Zealand Pharma, where glucagon activation boosts metabolic rate.

The fat-loss tail of the HGH molecule, isolated and used alone. Goal: trigger lipolysis without GH's water retention or insulin impact.

A weight-loss shot already approved in China. Innovent Biologics' GLP-1 + glucagon dual agonist out of China, with strong Phase 3 data and a 2025 China approval for obesity.

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.

A weight-loss drug for rare genetic forms of obesity. An MC4R agonist, FDA-approved in 2020 for obesity due to POMC, PCSK1, or LEPR deficiency and in 2022 for Bardet-Biedl syndrome; it's the educational anchor for melanocortin-pathway weight regulation.

A mealtime injection that curbs appetite and steadies blood sugar in diabetics. A synthetic analog of amylin (the satiety hormone co-secreted with insulin), FDA-approved in 2005 as a mealtime adjunct in type 1 and type 2 diabetes, and the clinical predecessor to Cagrilintide.

Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor.

Altimmune's GLP-1 + glucagon dual agonist. Phase 2 data shows weight loss alongside meaningful liver-fat reduction (NASH/MASH applications). Direct competitor to Retatrutide and Survodutide.

Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide.